Comparative Pharmacology
Head-to-head clinical analysis: ANGIOMAX RTU versus HEPARIN SODIUM 20 000 UNITS AND DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANGIOMAX RTU versus HEPARIN SODIUM 20 000 UNITS AND DEXTROSE 5 IN PLASTIC CONTAINER.
ANGIOMAX RTU vs HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Direct thrombin inhibitor that reversibly binds to the active site of thrombin, blocking its interaction with substrates (fibrinogen, factor V, VIII, XIII, and protein C).
Heparin binds to antithrombin III, accelerating its inhibition of thrombin (factor IIa) and activated factor X (Xa), thereby preventing fibrin formation. Dextrose 5% provides caloric support.
1 mg/kg intravenous bolus, followed by 0.15 mg/kg/min continuous intravenous infusion for up to 4 hours during percutaneous coronary intervention (PCI). For patients with heparin-induced thrombocytopenia (HIT) undergoing PCI, bolus 0.75 mg/kg, then 1.75 mg/kg/hour infusion for 4 hours.
IV: Initial bolus 80 units/kg, then continuous infusion at 18 units/kg/hr; adjust based on aPTT. Typical concentration: 20,000 units heparin in 500 mL D5W (40 units/mL).
None Documented
None Documented
The terminal elimination half-life of bivalirudin is approximately 25 minutes in patients with normal renal function. In patients with moderate to severe renal impairment, the half-life is prolonged (e.g., up to 1 hour in patients with creatinine clearance <30 mL/min, and up to 3-4 hours in dialysis-dependent patients). This is clinically relevant for dosing adjustments and monitoring of anticoagulation.
30–150 minutes (mean 90 min) for continuous IV infusion; shorter with higher doses due to saturable clearance. Prolonged in hepatic or renal impairment.
Bivalirudin is cleared by a combination of renal elimination (approximately 20% unchanged in urine) and proteolytic cleavage (hepatic metabolism and other proteases). Renal clearance accounts for about 20% of total clearance. Fecal excretion is negligible (<1%).
Renal: negligible at therapeutic doses; hepatic metabolism to uroheparin and low molecular weight species; biliary/fecal: minimal. Clearance is dose-dependent and saturable.
Category C
Category A/B
Anticoagulant
Anticoagulant